Recent advances in the research and development of CB1 antagonists

IDrugs

Volumn 8, Issue 1, 2005, Pages 53-66

  Smith, Roger A ^a   Fathi, Zahra ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Anorexigenic; Antagonist; Appetite; Cannabinoid; CB1; Obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ADIPONECTIN; AVE 1625; C REACTIVE PROTEIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDANTOIN DERIVATIVE; IMIDAZOLE DERIVATIVE; LEPTIN; NALOXONE; O 889; OPIATE ANTAGONIST; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; RIMONABANT; THIAZOLE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANOREXIA; BODY WEIGHT; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; FEEDING BEHAVIOR; FOOD INTAKE; HYPERPHAGIA; MOUSE; NONHUMAN; OBESITY; RAT; REVIEW; REWARD; WEIGHT REDUCTION;

ANIMALS; CANNABINOIDS; HUMANS; OBESITY; RECEPTOR, CANNABINOID, CB1; TECHNOLOGY, PHARMACEUTICAL;

EID: 13444274769     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Flier JS: Obesity wars: Molecular progress confronts an expanding epidemic. Cell (2004) 116(2):337-350.
2. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab (2004) 89(6):2583-2589.
3. Stein CJ, Colditz GA: The epidemic of obesity. J Clin Endocrinol Metab (2004) 89(6):2522-2525.
4. Weigle DS: Pharmacological therapy of obesity: Past, present, and future. J Clin Endocrinol Metab (2003) 88 6):2462-2469.
5. Bays H, Dujovne C: Anti-obesity drug development. Expert Opin Investig Drugs (2002) 11(9):1189-1204.
6. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P et al: SR-141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 350(2-3 ):240-244.
7. Sanofi-Synthélabo Information Meeting, February 2001; Paris, France: Sanofi-Synthélabo (2001). http://www.sanofi-synthelabo.fr
8. Sanofi-Synthélabo Information Meeting, February 2004; Paris, France: Sanofi-Synthélabo (2004). http://www.sanofi-synthelabo.fr
9. Aventis Company Presentation, June 2004, Strasbourg, France: Sanofi-Aventis (2004). http://www.aventis.com
10. Barth F, Rinaldi-Carmona M: The development of cannabinoid antagonists. Curr Med Chem (1999) 6(8):745-755.
11. Goya P, Jagerovic N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin Ther Pat (2000) 10(10):1529-1538.
12. Adam J, Cowley P: Recent advances in the cannabinoids. Expert Opin Ther Pat (2002) 12(10):1475-1489.
13. Palmer SL, Thakur GA, Makriyannis A: Cannabinergic ligands. Chem Phys Lipids (2002) 121(1-2):3-19.
14. 1 cannabinoid receptor antagonists. Curr Opin Drug Discovety Dev (2004) 7 4):498-506.
15. Hertzog DL: Recent advances in the cannabinoids. Expert Opin Ther Pat (2004) 14(10):1435-1452.
16. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346(6284):561-564.
17. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365(6441):61-65.
18. Lutz B: Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids (2002) 66(2-3 ):123-142.
19. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 54(2 ):161-202.
20. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258(5090):1946-1949.
21. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 50(1):83-90.
22. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 215(1):89-97.
23. Stella N, Schweitzer P, Piomelli D: A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 388(6644):773-778.
24. Sugiura T, Waku K: Cannabinoid receptors and their endogenous ligands. J Biochem (Tokyo) (2002) 132(1 ):7-12.
25. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Disc (2004) 3(9):771-784.
26. Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci (2003) 4(11):873-884.
27. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacol (2004) 47(Suppl 1):345-358.
28. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC: Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA (1990) 87(5):1932-1936.
29. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC: Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci (1991) 11(2):563-583.
30. Glass M, Dragunow M, Faull RL: Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience (1997) 77(2):299-318.
31. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U: Endogenous cannabinoid system as a modulator of food intake. Int J Obesity Relat Metab Disord (2003) 27 3):289-301.
32. Kirkham TC, Williams CM: Endogeneous cannabinoids and appetite. Nutr Res Rev (2001) 14(1):65-86.
33. Romero J, Wenger T, de Miguel R, Ramos JA, Fernandez-Ruiz JJ: Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation. Life Sci (1998) 63 5):351-356.
34. Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol (2001) 134(6):1151-1154.
35. Friedman JM: Leptin, leptin receptors and the control of body weight. Eur J Med Res (1997) 2(1):7-13.
36. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410(6830):822-825.
37. Kirkham TC, Williams CM, Fezza F, Di Marzo V: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 136 4):550-557.
38. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 112(3):423-431.
39. 1 receptor deleted mice. Neurosci Lett (2003) 343(3):216-218.
40. 1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology (2004) 145 7):3224-3231.
41. 1-receptor inverse agonist on body weight loss in obese and lean mice. Pharmacol Biochem Behav (2004) 77(1):117-125.
42. 1 receptor antagonist SR-141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol (2004) 143(5):520-523.
43. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 22(21):9612-9617.
44. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP et al: A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem (1997) 272 35)22330-22339.
45. 1 receptor. Eur J Pharmacol (1997) 334(1 ):R1-R2.
46. 1 cannabinoid receptor: Biochemical and pharmacological characterization. J Pharmacol Exp Ther (2004) 310(3):905-914.
47. Verty AN, McGregor IS, Mallet PE: Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett (2004) 354(3):217-220.
48. 1 receptor inverse agonist AM251 in mice. Behav Pharmacol (2003) 14(8):573-582.
49. De Vry J, Schreiber R, Eckel G, Jentzsch KR: Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR-141716A. Eur J Pharmacol (2004) 483(1):55-63.
50. 9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR-141716. Psychopharmacology (Berl) (2003) 165(4):370-377.
51. Werner NA, Koch JE: Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res (2003) 967(1-2):290-292.
52. Gardner EL, Vorel SR: Cannabinoid transmission and reward-related events. Neurobiol Dis (1998) 5(6 Pt B):502-533.
53. Harrold JA, Williams G: The cannabinoid system: A role in both the homeostatic and hedonic control of eating? Br J Nutr (2003) 90(4):729-734.
54. Yeomans MR, Gray RW: Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev (2002) 26 6):713-728.
55. Levine AS, Billington CJ: Opioids as agents of reward-related feeding: A consideration of the evidence. Physiol Behav (2004) 82(1):57-61.
56. Pietras TA, Rowland NE: Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats. Eur J Pharmacol (2002) 442(3):237-239.
57. Verty AN, Singh ME, McGregor IS, Mallet PE: The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (2003) 168(3):314-323.
58. Rowland NE, Mukherjee M, Robertson K: Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (2001) 159(1):111-116.
59. Kirkham TC, Williams CM: Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (2001) 153(2):267-270.
60. 9THC hyperphagia by SR-141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav (2002) 71(1-2):333-340.
61. Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM: Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res (2004) 999(2):227-230.
62. 1 antagonist SR-141716A and the opioid antagonist LY255582 on body weight and food intake. Abstr Endocrine Soc (2004) 86 P2-P6.
63. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci (1998) 63(8):PL113-PL117.
64. 1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (2003) 167 1):103-111.
65. 1 receptor antagonist SR-141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol (2003) 63(4):908-914.
66. 1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol (2003) 462 1-3):125-132.
67. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol - Regulat Integrat Comparat Physiol (2003) 284(2):R345-R353.
68. 1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther (2002) 301(3):915-924.
69. 1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obesity Relat Metab Disord (2004) 28(4):640-648.
70. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995) 270(45):26746-26749.
71. Gil-Campos M, Canete RR, Gil A: Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr (2004) 23 5):963-974.
72. Fernandez JR, Allison DB: Rimonabant Sanofi-Synthélabo. Curr Opin Invest Drugs (2004) 5(4):430-435.
73. Black SC: Cannabinoid receptor antagonists and obesity. Curr Opin Invest Drugs (2004) 5(4):389-394.
74. 1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol (2003) 477(3):213-217.
75. 1) receptor antagonist, rimonabant (SR-141716). Neuropsychopharmacology (2005) 30(1):145-155.
76. 1 antagonist N-piperidinyl-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther (2003) 306(1):93-102.
77. 1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. Eur J Pharmacol (2004) 498(1-3):119-123.
78. Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A: Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 42(4):769-776.
79. 1 receptor recognition and activation. J Pharmacol Exp Ther (2001) 296 3):1013-1022.
80. 1 cannabinoid receptor. J Med Chem (2002) 45(7 ):1447-1459.
81. 1 receptor antagonist N (piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl -4-methyl-1H pyrazole-3-carboxamide (SR-141716). J Med Chem (2002) 45 13):2708-2719.
82. Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG: Synthesis, structure-activity relationship, and evaluation of SR 141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem (2003) 46 4):642-645.
83. Reggio PH: Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Design (2003) 9(20):1607-1633.
84. 1 receptor. Mol Pharmacol (2002) 62(6):1274-1287.
85. 1 receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 46 24):5139-5152.
86. 1 cannabinoid receptor antagonists. J Med Chem (2004) 47(3):627-643.
87. Press Release, May 17, 2004: Solvay Pharmaceuticals (2004). http://www.solvaypress.com
88. 1 receptor antagonists related to SR-141716. Bioorg Med Chem Lett (2004) 14(5):1151-1154.
89. 1 cannabinoid receptor antagonists. J Med Chem (2005) 48: in press.
90. Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Navarro M, Serrano A, Rodriguez de Fonseca F, Dannert MT, Alsasua A, Suardiaz M, Pascual D et al: Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H 1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem (2004) 47 11):2939-2942.
91. 1 cannabinoid receptor ligands and potential antagonists: Synthesis, lipophilicity, affinity, and molecular modeling. J Med Chem (2002) 45(9):1748-1756.
92. 2 receptors. Eur J Pharmacol (2004) 495(1):43-53.
93. Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR: SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav (2002) 74(1):31-40.
94. 2 cannabinoid receptors. Bioorg Med Chem (2003) 11(2):251-263.
95. 1 receptor antagonists. Chem Pharm Bull Tokyo (2002) 50(8 ):1109-1113.
96. 1 cannabinoid receptor. J Pharmacol Exp Ther (2003) 306(1):363-370.
97. 1 cannabinoid receptor antagonist. Magn Reson Chem (2003) 41(4):265-268.
98. Sanofi (Barth F, Casellas P, Congy C, Martinez S, Carmona M): Preparation of pyrazole derivatives as cannabinoid receptor ligands. EP-00576357 (1993).
99. Sanofi (Barth F, Casellas P, Congy C, Martinez S, Rinaldi M, Anne-Archard G): Preparation of N-piperidino-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide as a cannabinoid receptor antagonist. EP-00656354 (1995).
100. University of Connecticut (Makriyannis A, Liu Q): Preparation of pyrazole derivatives as cannabinoid receptor antagonists. WO-01029007 (2001).
101. University of Connecticut (Makriyannis A, Liu Q): Novel pyrazole analogs acting on cannabinoid receptors. WO-03020217 (2003).
102. Virginia Commonwealth University & Organix Inc (Martin BR, Razdan RK, Mahadevan A): Pyrazole cannabinoid agonist and antagonists. US-06509367 (2003).
103. 1 receptor binding selectivity and methods for their production and use. WO-03088968 (2003).
104. Sanofi-Synthélabo (Camus P, Martinez S, Rinaldi M): Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them. WO-00046209 (2000).
105. 1 antagonists. WO-04058744 (2004).
106. Pfizer (Dow RL): Cannabinoid receptor ligands and uses thereof. WO-04035566 (2004).
107. 1 receptor antagonists. WO-04052864 (2004).
108. 1 antagonistic activity. WO-01070700 (2001).
109. 1-antagonistic activity. WO-02076949 (2002).
110. 1 antagonistic activity. WO-03026647 (2003).
111. 1 antagonistic activity. WO-03026648 (2003).
112. Merck & Co Inc (Finke PE, Mills SG, Plummer CW, Shah SK, Truong QT): Substituted Imidazoles as cannabinoid receptor modulators. WO-03007887 (2003).
113. 1 antagonistic activity. WO-03027076 (2003).
114. Bayer Pharmaceuticals Corp (Smith RA, O'Connor SJ, Wirtz S-N, Wong WC, Choi S, Kluender HC, Ning S, Wang G, Achebe F, Ying S): Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity. WO-03040107 (2003).
115. Merck & Co Inc (Hagmann WK, Qi H, Shah SK): Substituted imidazoles as cannabinoid receptor modulators. WO-03063781 (2003).
116. 1 receptor inverse agonists. WO-04060870 (2004).
117. Consejo Superior De Investigaciones Cientificas/Universidad Rey Juan Carlos (Jagerovic N, Goya Laza MP, Hernandez Folgado L, Alcorta Osoro IJ, Martin Fontelles MI, Suardiaz García ML, Dannert MT): 1,2,4-Triazole derivatives with cannabinoid properties. WO-03082833 (2003).
118. 1 receptor ligands. WO-04026301 (2004).
119. 1 receptor antagonists. WO-04060888 (2004).
120. Bayer Pharmaceuticals Corp (Smith RA, Kluender HC, Ning S, Lavoie R, Fan J): Preparation and use of pyrrole derivatives for treating obesity. WO-03027069 (2003).
121. 1 antagonistic, agonistic or partial agonistic activity. WO-03078413 (2003).
122. 1 ligands. WO-04058255 (2004).
123. AstraZeneca (Wilterman JM, Berggren AIK): Pyrazine compounds and pharmaceutical compositions containing them. WO-03051850 (2003).
124. 1 antagonists. WO-03051851 (2003).
125. Merck & Co Inc (Kopka IE, Li B, Hagmann WK): Preparation of substituted pyrimidines for treating disorders mediated by the Cannabinoid-1 receptor. WO-04029204 (2004).
126. Sanofi-Synthélabo (Barth F, Martinez S, Rinaldi-Carmona M): Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives. WO-03084930 (2003).
127. Merck & Co Inc (Finke PE, Meurer L, Debenham JS, Toupence RB, Walsh TF): Substituted 2,3-diphenyl pyridines. WO-03082191 (2003).
128. Sanofi-Synthélabo (Barth F, Martinez, S, Rinaldi-Carmona M): Terphenyl derivatives, preparation thereof, compositions containing same. WO-03084943 (2003).
129. 1 receptor antagonists. WO-00015609 (2000).
130. Aventis Pharma SA (Achard D, Bouchard H, Bouquerel J, Filoche B, Grisoni S, Hittinger A, Myers M): Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof. WO-01064633 (2001).
131. 1 receptor antagonist and a sibutramine for treating obesity. WO-02028346 (2002).
132. 1 receptor antagonist and an agent activating dopaminergic neurotransmission in the brain. WO-03018060 (2003).
133. 1 receptor antagonists). WO-04037823 (2004).
134. Pfizer (Griffith DA): Cannabinoid receptor ligands and uses thereof. US-04157838 (2004).
135. Pfizer (Griffith DA): Cannabinoid receptor ligands and uses thereof. US-04157839 (2004).
136. Merck & Co Inc (Toupence RB, Debenham JS, Goulet MT, Madsen-Duggan CB, Walsh TF, Shah SK): Substituted furo[2,3-b pyridine derivatives. WO-04012671 (2004).
137. Bayer Pharmaceuticals Corp (Smith RA, Wong WC, O'Connor SJ, Choi S, Kluender HCE, Zhang Z, Lavoie RC, Fan J, Podlogar BL: Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity. WO-03027114 (2003).
138. Hoffmann-La Roche (Alanine A, Beleicher K, Guba W, Haap W, Kuber D, Luebbers T, Plancher JM, Rogers-Evans M, Schneider G, Zuegge J, Roche O): Novel benzodioxoles. WO-04013120 (2004).
139. Sanofi-Synthélabo (Barth F, Congy C, Martinez S, Rinaldi M): Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same. WO-01032663 (2001).
140. 1 receptor binding selectivity, and methods for their production and therapeutic use. US-03199536 (2003).
141. Merck & Co Inc (Hagmann WK, Lin LS, Shah SK, Guthikonda RN, Qi H, Chang LL, Liu P, Armstrong HM, Jewell JP, Lanza TJ Jr): Substituted amides. WO-03077847 (2003).
142. Merck & Co Inc (Hagmann WK, Lin LS, Shah SK): Substituted aryl amides. WO-03087037 (2003).
143. Merck & Co Inc (Castonguay LA, Hagmann WK, Lin LS, Shah SK): Bicyclic amides. WO-03086288 (2003).
144. Merck & Co Inc (Hagmann WK, Lin LS, Shah SK, Goulet MT, Jewell JP): Spirocyclic amides as cannabinoid receptor modulators. WO-03082190 (2003).
145. Merck & Co Inc (Lin LS, Hagmann WK, Kumar S, Yin W, Doss G): Substituted amides. WO-04058145 (2004).